Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia. / Brøsen, Julie Maria Bøggild; Agesen, Rikke Mette; Kristensen, Peter Lommer; Alibegovic, Amra Ciric; Andersen, Henrik Ullits; Beck-Nielsen, Henning; Gustenhoff, Peter; Hansen, Troels Krarup; Hedetoft, Christoffer; Jensen, Tonny; Stolberg, Charlotte Røn; Juhl, Claus Bogh; Lerche, Susanne Søgaard; Nørgaard, Kirsten; Parving, Hans Henrik; Tarnow, Lise; Thorsteinsson, Birger; Pedersen-Bjergaard, Ulrik.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 6, 2023, p. 1557-1565.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia
AU - Brøsen, Julie Maria Bøggild
AU - Agesen, Rikke Mette
AU - Kristensen, Peter Lommer
AU - Alibegovic, Amra Ciric
AU - Andersen, Henrik Ullits
AU - Beck-Nielsen, Henning
AU - Gustenhoff, Peter
AU - Hansen, Troels Krarup
AU - Hedetoft, Christoffer
AU - Jensen, Tonny
AU - Stolberg, Charlotte Røn
AU - Juhl, Claus Bogh
AU - Lerche, Susanne Søgaard
AU - Nørgaard, Kirsten
AU - Parving, Hans Henrik
AU - Tarnow, Lise
AU - Thorsteinsson, Birger
AU - Pedersen-Bjergaard, Ulrik
N1 - Publisher Copyright: © 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
PY - 2023
Y1 - 2023
N2 - Aim: To compare nocturnal glucose profiles according to hourly plasma glucose measurements during treatment with insulin degludec and insulin glargine U100 in a cohort of people with type 1 diabetes prone to nocturnal severe hypoglycaemia. Materials and methods: The HypoDeg trial is a 2-year investigator-initiated, randomized, controlled crossover trial in 149 participants randomized to treatment with insulin degludec and insulin glargine U100 for 12 months each. The 51 participants in this predefined substudy stayed at least one night in hospital during each treatment arm for plasma glucose samples to be taken. Endpoints were glucose profiles, including mean plasma glucose, glycaemic variability and risk of hypoglycaemia. Results: There were no differences between treatments regarding mean plasma glucose. We saw a flatter glucose profile during insulin degludec compared with insulin glargine U100 treatment, which had a nadir at 4:00 AM, with a subsequent rise. During treatment with insulin degludec, the participants had lower glycaemic variability, with an estimated treatment difference of −4.3% (95% confidence interval [CI] −8.1 to −0.5; P < 0.05). Participants treated with insulin degludec were less likely to experience nocturnal hypoglycaemia below 3.0 mmol/L (hazard ratio 0.36 [95% CI 0.17-0.73; P < 0.05]). Conclusion: Based on nocturnal plasma glucose measurements, treatment with insulin degludec compared with insulin glargine U100 administered in the evening results in lower glycaemic variability and lower risk of nocturnal hypoglycaemia without differences in mean plasma glucose.
AB - Aim: To compare nocturnal glucose profiles according to hourly plasma glucose measurements during treatment with insulin degludec and insulin glargine U100 in a cohort of people with type 1 diabetes prone to nocturnal severe hypoglycaemia. Materials and methods: The HypoDeg trial is a 2-year investigator-initiated, randomized, controlled crossover trial in 149 participants randomized to treatment with insulin degludec and insulin glargine U100 for 12 months each. The 51 participants in this predefined substudy stayed at least one night in hospital during each treatment arm for plasma glucose samples to be taken. Endpoints were glucose profiles, including mean plasma glucose, glycaemic variability and risk of hypoglycaemia. Results: There were no differences between treatments regarding mean plasma glucose. We saw a flatter glucose profile during insulin degludec compared with insulin glargine U100 treatment, which had a nadir at 4:00 AM, with a subsequent rise. During treatment with insulin degludec, the participants had lower glycaemic variability, with an estimated treatment difference of −4.3% (95% confidence interval [CI] −8.1 to −0.5; P < 0.05). Participants treated with insulin degludec were less likely to experience nocturnal hypoglycaemia below 3.0 mmol/L (hazard ratio 0.36 [95% CI 0.17-0.73; P < 0.05]). Conclusion: Based on nocturnal plasma glucose measurements, treatment with insulin degludec compared with insulin glargine U100 administered in the evening results in lower glycaemic variability and lower risk of nocturnal hypoglycaemia without differences in mean plasma glucose.
KW - basal insulin
KW - clinical trial
KW - glycaemic control
KW - hypoglycaemia
KW - insulin analogues
KW - type 1 diabetes
U2 - 10.1111/dom.15003
DO - 10.1111/dom.15003
M3 - Journal article
C2 - 36749303
AN - SCOPUS:85149986760
VL - 25
SP - 1557
EP - 1565
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 6
ER -
ID: 359552663